3B-NEO | Comprehensive Genetic Screening for Newborn

A mother gently holding her sleeping newborn baby

Product

3B-NEO

Comprehensive Genetic Screening for Newborn

Why Genomic Newborn Screening?

Traditional newborn screening has limitations. Biochemical screening may miss genetically detectable disorders or identify them only after disease progression.

Earlier Detection Before Biochemical Changes Appear
Higher Sensitivity for Hard-to-Detect Conditions
Actionable Insights from a Single Test
Early Genetic Answers: Prevent Diagnostic Odyssey

What 3B-NEO Screens For?

3B-NEO analyzes 595 genes associated with serious, clinically actionable pediatric-onset genetic conditions, selected based on clinical actionability and potential impact on lifelong health outcomes.

Includes screening for

Inborn Errors of Metabolism
Immunologic Disorders
Neuromuscular Conditions
Other Actionable Pediatric-Onset Conditions

Selected conditions are those that

Present in infancy or childhood
Benefit from early intervention
Can alter lifelong health outcomes when detected early

A Simple Workflow for Busy Providers

STEP 1
Parents initiated
Test requests made by the family. Parents request the tests directly.
STEP 2
One-click
physician review
Confirm with a single click and send the sample. Minimal additional steps for you.
STEP 3
End-to-end
logistics support
3billion manages all logistics — kits are sent to you and samples are picked up.
STEP 4
Ready-to-share result
Results are shared through the system, ready to deliver to families.

Test Specification

Test Type: WGS & WES
Genes Included: 595 Genes
Turn Around Time: 2 weeks
Order Timing: From prenatal through 90 days after birth
Sampling Kits: Dried Blood Spot Card for Newborns

Download Sample Report

FAQ

- Most rare genetic disorders appear healthy at birth externally, yet internally, irreversible damage has already begun — a diagnostic latency period. By using genomic analysis to screen for hundreds of Actionable (medically treatable) conditions that conventional biochemical screening (MS/MS) cannot detect, 3B-NEO secures the therapeutic window before symptoms appear, enabling timely intervention.
- This goes beyond the early detection of disease, as timely interventions—such as dietary management, medication, or gene therapy—can prevent physical and intellectual disabilities and fundamentally improve the patient's lifelong prognosis.
3B-NEO strictly screens for conditions meeting all three of the following criteria:
- High likelihood of onset in childhood
- Clear evidence of clinical benefit from early intervention (Actionable)
- Significant impact on the child's lifelong quality of life.
Discrepancies between the two tests can occur because they serve different purposes and provide different types of information. Conventional NBS assesses 'current metabolic status,' while 3B-NEO identifies 'underlying genetic variants' — it is important to interpret them as complementary rather than conflicting.
Interpretation by scenario is as follows
- Conventional NBS Normal / 3B-NEO Variant Detected
  Current metabolic values are normal, but the child carries a genetic predisposition to potential future disease. Proactive monitoring and preventive measures should be considered.
- Conventional NBS Abnormal / 3B-NEO No Variant Detected
  This may be due to a transient physiological fluctuation or a non-genetic cause.
  However, if symptoms persist or there is clinical suspicion, additional genetic testing should be considered.
If a clinically significant variant is identified through 3B-NEO, the priority should be immediate clinical action rather than simply comparing the two tests.